CapseraGLP-1 receptor agonists
Compare the named medicines in this source-linked class directory.
Membership describes a named action or a component of a combination. A medicine may appear in several families. Medicines in one family are not automatically interchangeable; this is a study directory, not a prescribing guide.
No matching drugs. Try another name.
This medicine has additional actions; this family describes only one of them.
Generic names and pronunciation
Shared name ending: -glutide · Semaglutide, Dulaglutide, Liraglutide
| Semaglutide · sem-a-GLOO-tide |
| Dulaglutide · doo-la-GLOO-tide |
| Tirzepatide · tir-ZEP-a-tide |
| Liraglutide · LIR-a-GLOO-tide |
Pronunciation is shown for the US English generic name. A name ending is a memory cue, not a classification rule.
Body system and related classes
Body system: Endocrine
How each medicine works
| Semaglutide — GLP-1 analogue that selectively binds and activates the GLP-1 receptor; albumin binding gives it a long half-life. |
| Dulaglutide — Activates GLP-1 receptors on beta cells, raising cAMP for glucose-dependent insulin release; lowers glucagon, slows gastric emptying. |
| Tirzepatide — Activates both GIP and GLP-1 receptors; GLP-1 regulates appetite and caloric intake. A fatty diacid prolongs half-life. |
| Liraglutide — Acylated GLP-1 analog; activates the GLP-1 receptor (adenylyl cyclase-coupled) to improve glycemic control. |
Each summary is the mechanism line from the medicine’s study card.
What each medicine is used for
| Semaglutide — As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; Reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; Reduction of sustained eGFR decline, end-stage kidney disease or cardiovascular death in adults with type 2 diabetes and chronic kidney disease |
| Dulaglutide — Adjunct to diet and exercise for glycemic control in adults and children aged 10 years and older with type 2 diabetes; Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors |
| Tirzepatide — With reduced-calorie diet and increased physical activity, long-term weight reduction/maintenance in adults with obesity or overweight plus at least one weight-related comorbidity; With reduced-calorie diet and increased physical activity, moderate-to-severe obstructive sleep apnea in adults with obesity |
| Liraglutide — Adjunct to diet and exercise to improve glycemic control in adults and children aged 10 years and older with type 2 diabetes |
Each list is the uses line from the medicine’s study card.
Telling these medicines apart
Medicines in this class: 4
Not in the reviewed -glutide name-ending list: Tirzepatide
Tirzepatide — Dual GIP and GLP-1 receptor agonist; membership in this class reflects its GLP-1 action, not a single-target mechanism.
Listed on more than one card in this class
Common side effects
Nausea · 4/4: Semaglutide, Dulaglutide, Tirzepatide, Liraglutide
Vomiting · 4/4: Semaglutide, Dulaglutide, Tirzepatide, Liraglutide
Diarrhea · 4/4: Semaglutide, Dulaglutide, Tirzepatide, Liraglutide
Abdominal pain · 3/4: Semaglutide, Dulaglutide, Tirzepatide
Constipation · 3/4: Semaglutide, Tirzepatide, Liraglutide
Decreased appetite · 2/4: Dulaglutide, Liraglutide
Warnings
Acute pancreatitis · 4/4: Semaglutide, Dulaglutide, Tirzepatide, Liraglutide
Hypoglycemia with insulin or secretagogues · 3/4: Semaglutide, Dulaglutide, Liraglutide
Interactions
Oral medications (delayed gastric emptying) · 3/4: Semaglutide, Dulaglutide, Tirzepatide
Boxed warning
4/4: Semaglutide, Dulaglutide, Tirzepatide, Liraglutide
Same boxed-warning wording on: Dulaglutide, Tirzepatide
Listed on only one card in this class
Semaglutide: Warnings — Diabetic retinopathy complications · Interactions — Insulin secretagogues (e.g. sulfonylureas); Insulin
Dulaglutide: Warnings — Severe GI reactions / acute kidney injury · Interactions — Insulin secretagogues / insulin; Warfarin (narrow therapeutic index)
Tirzepatide: Warnings — Severe GI adverse reactions; Acute gallbladder disease · Interactions — Insulin or sulfonylureas
Liraglutide: Warnings — Acute kidney injury from volume depletion · Interactions — Oral drugs (delayed gastric emptying)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.